PROFILUL DE SIGURANȚĂ AL MEDICAMENTELOR ANTITUBERCULOASE
DOI:
https://doi.org/10.52692/1857-0011.2023.3-77.39Cuvinte cheie:
preparate antituberculoase, reacții adverse medicamentoase, epatotoxicitate, neurotoxicitate, isoniazida, rifampicina, linezolidRezumat
Studierea profilului de siguranță a medicamentelor antituberculoase prezintă o prioritate în elaborarea unui regim de tratament cît mai eficient și cu un grad inalt de tolerabilitate pentru pacienți. Dezvoltarea reacțiilor adverse a medicamentelor antituberculoase continuă să rămîna una din cauzele principale de complianță joasă sau chiar abandonarea tratamentului administrat. Depistarea, raportarea și analiza aprofundată a efectelor adverse asociate administrării medicamentelor antituberculoase, atît pentru medicamentele de prima linie, cât și de linia a doua, servește drept garant al unui tratament reușit.
Referințe
Arbex M., de Castro Lima Varella M., de Siqueira H., de Mello FAF. Anti-tuberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J Bras Pneumol. 2010;36:626-640.
Athira B., Manju C., Jyothi E. A study on adverse drug reactions to first line antitubercular drugs in DOTS therapy. International Journal of Pharmacology and Clinical Sciences. 2015;4(1):7–11.
Bacinschi N., Alexandru S., Donica A., Nepoliuc L., Ceban S., Crivenco L. Hepatotoxicitatea preparatelor antituberculoase. Revistă ştiinţifico-practică Sănătate publică, Economie şi Management în medicină. 2020; 1(83), p.12.
Baghaei P., Tabarsi P., Chitsaz E., et al. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to anti-tuberculous agents in new tuberculosis cases. Am J Therapeut. 2010;17:17-22.
Baghaei P., Tabarsi P., Dorriz D., et al. Adverse effects of MDRTB treatment with a standardized regimen: a report from Iran. Am J Therapeut. 2011;18:p.29-34.
Carroll M., Lee M., Cai Y., et al. Frequency of adverse reactions to firstand second-line anti-tuberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis. -2012;167:961-966.
Chhetri A., Saha A., Verma S., Palaian S., Mishra P., Shankar P. A study of adverse drug reactions caused by first line anti-tubercular drugs used in Directly Observed Treatment, Short course (DOTS) therapy in western Nepal, Pokharan. J Pak Med Assoc. 2008;58:531-536.
Diacon A., Pym A., Grobusch M. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371:723-732.
Garg R., Gupta V., Mehra S., Singh R., Prasad R. Rifampicin induced thrombocytopenia. Indian J Tuberc. 2007;54:94-96.
Garg R., Verma S., Mahajan V., Prasad R. Exfoliative dermatitis secondary to ethambutol and pyrazinamide. Internet J Pulm Med. 2008;9:1.
Gerdan G., Nurullah A., Ucan E., Bulac Kir S. Paradoxical increase inuricacid level with allopurinol use inpyrazinamideinduced hyperuricemia. Singap Med J. 2013;54:p.125-128.
Jeong I., Park JS., Cho YJ. et al. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci. 2015 Feb;30(2):167-72.
Kang BH., Jo KW., Shim TS. Current status of fluoroquinolone use for treatment of tuberculosis in a tertiary care hospital Korea. Tuberc Respir Dis (Seoul). 2017;80:143-152.
Kant S., Verma SK., Gupta V., Anand SC., Prasad R. Pyrazinamide induced thrombocytopenia. Indian J Pharmacol.2010;42:108-109.
Khalili H. Dashti-Khaviadaki S., Rasolinejad M. et al. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome. Daru. 2009, v.17, N.3, p.163-167.
Kurniawati F., Sulaiman SAS., Gillani SW. Adverse drug reactions of primary anti-tuberculosis drugs among tuberculosis patients treated in chest clinic. International Journal of Pharmacy and Life Sciences. 2012;3(1):1331–1338.
Lv X., Tang S., Xia Y., et al. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study. PLoS One. 2013;8, p.65037.
Potter JL., Capstick T., Ricketts WM., Whitehead N., Kon OM. AUK-based resource to support the monitoring and safe use of anti-tuberculosis drugs and second-line treatment of multidrug-resistant tuberculosis. TB Drug Monographs. 2015:90-96.
Prasad R., Singh A., Srivastava R., et al. Adverse drug reaction in the treatment of multi drug resistant tuberculosis. Indian J Tuberc. 2016;63:106-114.
Ramappa V., Aithal G.P. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. Clin Exp Hepatol. 2013, Mar; 3(1): 37–49.
Richardson M. et al. Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review meta-analysis (protocol). Systematic Review. 2017, 6, p. 142.
Sarin R., Behera D., Khanna A., Singh V., Narang P., Deepak TS. Second-line injectable induced ototoxicity in drug resistant tuberculosis: a systematic review of Indian studies. Indian J Tuberc. 2019;66:279-287.
Schnippel K., Firnhaber C., Berhanu R., Page-Shipp L., Sinanovic E. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:1871-1879.
Shinde KM., Pore SM., Bapat TR. Adverse reactions to first-line anti-tuberculous agents in hospitalised patients: pattern, causality, severity and risk factors. Indian J Med Specialities. 2013;4:1-4.
Singh A., Prasad R., Balasubramanian V., Gupta N., Gupta P. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. Clinical Epidemiology and Global Health. 2015;3:80–90.
Sinha K., Marak IT., Singh W. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy: experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, India. The Journal of Association of Chest Physicians. 2013;1(2):50.
Tang S., Yao L., Hao X., et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45:161-170.
Tawanda G. Chemotherapy of Tuberculosis, mycobacterium Avium Complex Disease and Leprosy. Goodman and Gilman’s the Pharmacological Basis of the Therapeutics. 12th ed. McGraw Hill Med; 2011:1559.
Vedove CD., Del Giglio M., Schena D., Girolomoni G. Drug induced lupus erythematosus. Arch Dermatol Res. 2009;301:99-105.
Verma R., Mahor GR., Shrivastava AR., Pathak P. Adverse drug reactions associated with first-line anti-tubercular drugs in a tertiary care hospital of Central India: a study of clinical presentations, causality and severity. Asian J Pharm Clin Res. 2014;7(5):140–143.
World Health Organisation. Global tuberculosis report 2016. Geneva, Switzerland: WHO; 2016/CDS/ TB/2016.8.
World Health Organization. Global Tuberculosis Report 2018. Geneva: WHO; 2018/CDS/TB/2018.20.
World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva: WHO; 2019 (WHO/CDS/TB/2019.7)
Wu S., Zhang Y., Sun F., et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Therapeut.2016;23:p.521-530.
Yakar F., Yildiz N., Yakar A., Kilicaslan Z. Isoniazid-and rifampicin-induced thrombocytopenia. Multidiscip Respir Med. 2013;8:13.
Yang TW., Park HO., Jang HN., et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study. Medicine (Baltimore). 2017;96, p.7482.
Вольф С. Б. Нежелательные побочные реакции на химиотерапию туберкулеза. Журнал Гродненского государственного медицинского университета. 2016; 3, с.141-146.
Descărcări
Publicat
Număr
Secțiune
##category.category##
Licență
Copyright (c) 2024 Buletinul Academiei de Științe a Moldovei. Științe medicale
Această lucrare este licențiată în temeiul Creative Commons Attribution 4.0 International License.
